We are a biopharmaceutical company that has developed ONS-5010/LYTENAVA TM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD. In June 2025, we…
The business is unprofitable at the operating level (-4744.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$52M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$1M
Net Income (TTM)
-$61M
▲ +17.2% YoY
Op. Margin
-4744.25%
ROIC
-19929.11%
▲ +18078.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$47M
▲ +24.7% YoY
Op. Cash Flow (TTM)
-$47M
▲ +24.7% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
3Y CAGR: -28.2%
Continue Research